Buckeyes, yes it is hard to try and figure how the BoD of this company squares a few things. IMO how they and senior management can defend their almost total abandonment of fiduciary duty is a huge question. I think they have been continually "swinging for the fences" while at the same time eschewing anything that even resembles good business practice.

It is also mind boggling how Hepalink lets the company continue in this manner.  They have sunk in excess of $100 million into a company that is at a standstill while they know full well they only see ROI with increased equity value and future cash flow resultant from sales of an approved drug in their territory and elsewhere. Insolvency likely means loss of their license as well as their equity wipeout yet they seem to support the status quo. With all the positives on the science side it would seem that they would have a vested interest in moving the business side along. 

As you say, June 20 is approaching quickly, it will be interesting to see if anything of substance is presented before or at that time.